iota Biosciences is a bioelectronic medicine company developing ultra-miniaturised implantable neural interface devices powered and controlled via ultrasound. The company’s core technology enables wireless energy delivery and communication to sub-millimetre implants, eliminating the need for batteries and significantly reducing device size compared to conventional neuromodulation systems. This approach enables minimally invasive, injection-based implantation procedures.

The platform is designed to interface with peripheral nerves to modulate physiological functions across a range of indications, including inflammatory diseases and organ-specific disorders. By leveraging ultrasonic power transfer, iota’s devices can be deeply implanted while remaining externally controllable, creating a new class of distributed bioelectronic therapies that can target precise neural pathways without the constraints of wired or battery-powered systems.

iota Biosciences was acquired by Astellas Pharma and is now positioned as part of a broader strategy to develop bioelectronic medicines alongside traditional pharmacological therapies. Its technology is best understood as enabling infrastructure for next-generation neuromodulation, with potential applications across multiple therapeutic areas where precise, minimally invasive neural control is required.